Daiichi Sankyo develops and markets pharmaceuticals. The Company offers therapies in the areas of hypertension, dyslipidemia, diabetes, acute coronary syndrome, metastatic melanoma, cardiology, oncology, pain, and other aspects. It serves customers in the United States and internationally.

Type
Public
HQ
Parsippany-Troy Hills, US
Size (employees)
3,168 (est)
Daiichi Sankyo is headquartered in Parsippany-Troy Hills, US
Report incorrect company information

Key People/Management at Daiichi Sankyo

George Nakayama

George Nakayama

Representative Director, Chairman and CEO
Sunao Manabe

Sunao Manabe

Representative Director, Member of the Board, President and COO
Kazunori Hirokawa

Kazunori Hirokawa

Representative Director, Member of the Board
Toshiaki Sai

Toshiaki Sai

Member of the Board, Executive Vice President and CFO
Katsumi Fujimoto

Katsumi Fujimoto

Member of the Board, Senior Executive Officer
Noritaka Uji

Noritaka Uji

Member of the Board (Outside)
Show more

Daiichi Sankyo Office Locations

Daiichi Sankyo has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
2 Hilton Ct
Show all (1)
Report incorrect company information

Daiichi Sankyo Financials and Metrics

Daiichi Sankyo Financials

Market capitalization (27-Oct-2017)

14.7 b

Closing share price (27-Oct-2017)

22
Daiichi Sankyo's current market capitalization is $14.7 b.
Show all financial metrics
Report incorrect company information

Daiichi Sankyo News and Updates

Daiichi Sankyo partners with Crohn’s & Colitis Foundation to draw attention to iron deficiency

A new disease awareness campaign from Daiichi Sankyo highlights iron deficits common in patients with Crohn’s disease and ulcerative colitis. Daiichi is working with the Crohn’s & Colitis Foundation on the campaign, Called “Get Iron Informed,” to encourage patients with inflammatory bowel diseas…

FiercePharmaAsia—GSK’s neurology R&D hub, Pfizer-Astellas’ aborted Xtandi mission, Daiichi Sankyo’s Benicar settlement

GlaxoSmithKline will soon close its global neuroscience R&D hub located in Shanghai, Pfizer and Astellas have decided to discontinue research into Xtandi's usage in breast cancer, Daiichi Sankyo is offering $300 million to settle about 2,300 lawsuits around Benicar and other news items from Asia…
Report incorrect company information